Leerink Partners Maintains CVS Health(CVS.US) With Hold Rating, Maintains Target Price $60
Analysts Have Conflicting Sentiments on These Healthcare Companies: CVS Health (CVS), Pharvaris (PHVS) and United Therapeutics (UTHR)
CVS Health Analyst Ratings
Argus Adjusts Price Target on CVS Health to $75 From $80, Maintains Buy Rating
Mizuho Securities Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $72
Buy Rating for CVS Health: A Cautiously Optimistic Outlook Amidst Revised Guidance and Strong Fundamentals
Mizuho Adjusts Price Target on CVS Health to $66 From $72, Maintains Outperform Rating
CVS Health Analyst Ratings
Wells Fargo Adjusts Price Target on CVS Health to $61 From $60, Maintains Equalweight Rating
Hold Rating on CVS Health Amidst Anticipated Earnings Pressure and Segment Challenges
CVS Health Price Target Cut to $63.00/Share From $64.00 by Deutsche Bank
HSBC Adjusts Price Target on CVS Health to $61 From $62
Analysts' Opinions Are Mixed on These Healthcare Stocks: CVS Health (CVS), Insulet (PODD) and Artivion (AORT)
CVS Health (CVS) Gets a Buy From Evercore ISI
TD Cowen Remains a Hold on CVS Health (CVS)
Barclays Adjusts Price Target on CVS Health to $63 From $65
CVS Health Analyst Ratings
CVS Health: Hold Rating Justified by Mixed Financial Performance and Leadership Changes
CVS Health: A Buy Rating Backed by Strong Earnings Performance and Strategic Initiatives
Barclays Maintains CVS Health(CVS.US) With Hold Rating, Maintains Target Price $65